Key facts
- Cunde Medical Technology’s last known valuation is $9.3M (Nov 2019).
- It has raised $15.7M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Korea Investment Partners, TusStar Incubator, BGI Genomics, Beijing Health (Holdings), Chongqing Laimei Pharmaceutical — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Cunde Medical Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Cunde Medical Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cunde Medical Technology
Developer of biopharmaceutical products designed for cancer and advanced liver cirrhosis. The company offers personalised tumour vaccines, autologous dendritic cell therapies, peptide-drug conjugates, topical peptide ointments, and immune microenvironment modulation platforms, thereby enhancing immune response, inhibiting tumour growth, and reducing recurrence through targeted and innovative treatment approaches.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2016
- Employees
- 63
- Website
- cunde.com/
- Ownership
- Privately Held (backing)
Cunde Medical Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cunde Medical Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cunde Medical Technology in its N-PORT filings yet. We sweep new filings monthly.